1
Clinical Trials associated with Recombinant SARS-CoV-2 Vaccine (Hansenula Polymorpha)(Shenzhen Kangtai Biological Products Co., Ltd.)A Randomized, Blind and Parallel-Controlled Phase III Clinical Trial of Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18,31,33,45,52 and 58) Vaccine (Hansenula Polymorpha) to Evaluate the Efficacy of Infections and Related Disease Caused by HPV 6/11/16/18/31/33/45/52/58, Immunogenicity and Safety in Healthy
Start Date01 Jun 2021 |
Sponsor / Collaborator- |
100 Clinical Results associated with Recombinant SARS-CoV-2 Vaccine (Hansenula Polymorpha)(Shenzhen Kangtai Biological Products Co., Ltd.)
100 Translational Medicine associated with Recombinant SARS-CoV-2 Vaccine (Hansenula Polymorpha)(Shenzhen Kangtai Biological Products Co., Ltd.)
100 Patents (Medical) associated with Recombinant SARS-CoV-2 Vaccine (Hansenula Polymorpha)(Shenzhen Kangtai Biological Products Co., Ltd.)
100 Deals associated with Recombinant SARS-CoV-2 Vaccine (Hansenula Polymorpha)(Shenzhen Kangtai Biological Products Co., Ltd.)